Elotuzumab for the treatment of multiple myeloma

Table 1 Major clinical trials of elotuzumab that have published data

Study	NCT number (trial name)	Phase	N	Regimen	ORR	PFS rate	Median PFS (months)
Zonder 2012 [23]	NCT00425347 (HuLuc63-1701)	1	35^a	Elotuzumab (0.5–20 mg/kg)	0	–	–
Lonial 2012 [26, 27]	NCT00742560 (HuLuc63-1703)	1b	29^b	Elotuzumab (5–20 mg/kg) + Rd	82 %	–	32.9
Richardson 2015 [27]	NCT00742560 (HuLuc63-1703)	2	36	Elotuzumab (10 mg/kg) + Rd	92 %		32.5^c
Richardson 2015 [27]	NCT00742560 (HuLuc63-1703)	2	37	Elotuzumab (20 mg/kg) + Rd	76 %		25.0^c
Lonial 2015 [32]	NCT01239797 (ELOQUENT-2)	3	321	Elotuzumab (10 mg/kg) + Rd	79 %	1-year 68 %, 2-year 41 %	19.4
Lonial 2015 [32]	NCT01239797 (ELOQUENT-2)	3	325	Rd	66 %	1-year 57 %, 2-year 27 %	14.9
Mateos 2014 [34]	NCT01632150	2	40	Elotuzumab (10 mg/kg) + TD^d	40 %	–	–
Jakubowiak 2012 [35]	NCT00726869 (HuLuc63-1702)	1	28	Elotuzumab (2.5–20 mg/kg) + V	48 %		9.46^e
Palumbo 2015 [38] Jakubowiak 2016 [39]	NCT01478048	1/2	77^f	Elotuzumab (10 mg/kg) + VD	66 %	1-year 39 %, 2-year 18 %	9.7
Palumbo 2015 [38] Jakubowiak 2016 [39]	NCT01478048	1/2	75	VD	63 %	1-year 33 %, 2-year 11 %	6.9

N number; ORR objective response rate; PFS progression-free survival; Rd lenolidomide and dexamethasone; TD thalidomide and dexamethasone; V bortezomib; VD bortezomib and dexamethasone
^aThirty-four patients treated
^bTwenty-eight patients treated
^cMedian time to progression or death
^dCyclophosphamide was added if progressing between cycle 2 and 5 or not responding by cycle 5
^eMedian time to progression
^fSeventy-five patients treated

ISSN: 1756-8722